India Drug-Pricing Agency Rejects Appeals Of Three Drug Makers
This article was originally published in PharmAsia News
India's drug-pricing regulator rejected the appeals of Abbott Healthcare, Alembic Pharmaceuticals and Dr. Reddy's Laboratories of previously set price caps on their drugs.
You may also be interested in...
EU Regulatory Roundup, February 2020: Brexit And Swixit Threaten Huge Disruption Amidst MDR Uncertainty
Complying with the EU’s new Medical Device Regulation would be hard enough. But more layers of uncertainty – especially Brexit and Swixit ̶ mean European medtech is navigating very turbulent waters right now.
Fresenius Kabi has reported sales ahead by 6% in 2019, as growth in emerging markets helped to offset a subdued increase in North America. Meanwhile, the firm has pushed back financial expectations for its biosimilars by a year.
Fresenius Kabi and Vifor Pharma have agreed to create a joint venture in China for intravenous iron products.